Edaravone dexborneol sublingual is named as a drug or biological intervention in 3 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Simcere Pharmaceutical Co., Ltd (1), Peking Union Medical College Hospital (1) and Xinqiao Hospital of Chongqing (1). Registered phases: Phase 2, Phase 3 and Phase 4. Conditions studied include Post-stroke Cognitive Impairment; Cerebral Small Vessel Disease; Ischemic Stroke.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06674460 | Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease (ClinicalTrials.gov ↗) Cerebral Small Vessel Disease, Ischemic Stroke |
Phase 3 | Recruiting |
| NCT06315231 | Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients (ClinicalTrials.gov ↗) Post-stroke Cognitive Impairment |
Phase 2 | Recruiting |
| NCT07682922 | Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS) (ClinicalTrials.gov ↗) Acute Ischemic Stroke |
Phase 4 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Post-stroke Cognitive Impairment | 1 |
| Cerebral Small Vessel Disease | 1 |
| Ischemic Stroke | 1 |
| Acute Ischemic Stroke | 1 |
| Lead sponsor | Trials |
|---|---|
| Simcere Pharmaceutical Co., Ltd | 1 |
| Peking Union Medical College Hospital | 1 |
| Xinqiao Hospital of Chongqing | 1 |
| Register | Edaravone dexborneol sublingual trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Edaravone dexborneol sublingual works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Edaravone dexborneol sublingual (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.